Displaying 49 - 60 of 101
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Displaying 49 - 60 of 101